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Abstract
APOBEC3G is a cellular cytidine deaminase that was recently identified as the Vif-sensitive antiviral
host factor responsible for the restriction of vif-defective HIV-1 in primary human cells and certain
non-permissive T cell lines. Inhibition of HIV-1 replication is thought to be the result of
APOBEC3G-induced hypermutation of the viral genome that occurs early during reverse
transcription. Against this backdrop is a new report from the Uchiyama laboratory that proposes
deaminase-independent restriction of HTLV-1 by APOBEC3G (Sasada et al. Retrovirology 2005,
2:32). These findings combined with recent reports of deaminase-independent inhibition of
Hepatitis B virus as well as HIV-1 suggest that cytidine deaminase activity and antiviral activity may
be separable functional properties of APOBEC3G.
The identification of APOBEC3G (APO3G) in 2002 as the
long elusive cellular target of the HIV viral infectivity fac-
tor (Vif) [1] has triggered an outburst of research activity
that has produced in a short period of time a rather com-
prehensive working model for APO3G function (Fig. 1).
Although the details of this model are changing almost
daily, it is generally believed that APO3G does not inter-
fere with virus production from infected cells but acts at a
post-entry level to prevent the productive infection of new
target cells. This model is consistent with more than a dec-
ade worth of biological and genetic data demonstrating
that the Vif-sensitive host factor inhibits HIV-1 infectivity
when expressed in the virus-producing cell but does not
inhibit infection by HIV-1 when expressed in the target
cell (for review see [2]). It is clear that the antiviral activity
of APO3G requires its presence in progeny virions where
it can cause hypermutation of the viral genome during the
reverse transcription step early after infection. Hypermu-
tation of the viral genome at that stage of the viral replica-
tion cycle is thought to either result in mutational
inactivation of the viral genome – ensuing in the produc-
tion of defective virions in the next replication cycle – or
to trigger degradation of the viral genome in the target cell
by activating a host DNA repair mechanism thus resulting
in abortive infection (reviewed in [3]).
Primate lentiviruses such as HIV and SIV have adapted to
APO3G with the help of the virus-encoded vif gene whose
function is to prevent the packaging of APO3G into virus
particles (reviewed in [3]). However, APO3G can target
other viruses that do not encode a vif gene or a Vif-like
activity. Indeed, APO3G was shown to inhibit the replica-
tion of Hepatis B virus (HBV) [4] and was found to affect
the retrotransposition of endogenous retroviruses alike
[5]. Inhibition of retrotransposition was correlated with
G-to-A hypermutation of the endogenous retroviral
genomes [5] and APO3G-induced hypermutation of HBV
genomes was observed at least in one cell type [6]. How-
ever, APO3G-induced hypermutation of the HBV genome
seemed to be rare and inhibition of HBV by APO3G
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appeared to be primarily due to the suppression of viral
DNA synthesis through a deamination-independent
mechanism [4]. The precise mechanism of such deamina-
tion-independent suppression of HBV by APO3G remains
elusive. Also, the functional relevance of the APO3G-
based restriction of HBV replication in vivo remains to be
determined given the fact that expression of APO3G in
human hepatocytes – the primary target for HBV – is very
low.
Against this backdrop appeared a study by the Uchiyama
laboratory investigating the potential antiviral activity of
APO3G towards HTLV-1 (Sasada et al. Retrovirology
2005, 2:32). HTLV-1 differs from HIV-1 in that it produces
only very low levels of cell-free infectious virions suggest-
ing a mode of virus transmission that is dependent on
close cell-to-cell contacts [7,8]. Interestingly, the genetic
diversity of HTLV-1 is much lower than that of HIV-1 even
though both viruses target primarily APO3G-expressing
Inhibition of virus infectivity by APO3G Figure 1
Inhibition of virus infectivity by APO3G. Cells restrictive for the replication of Vif-defective HIV express the cytidine deaminase 
APOBEC3G (APO3G). In the absence of Vif, APO3G is packaged into virus particles (1). Such virions are capable of penetrat-
ing a target cell and initiate minus-strand cDNA synthesis ((-)-cDNA). However, APO3G causes hypermutation of the viral (-)-
cDNA resulting in the conversion of deoxycytidine to deoxyuridine (2). Deoxyuridine residues in the viral cDNA can be tar-
geted by uracil-DNA glycosylase, which could lead to endonucleolytic cleavage by endonucleases present in the target cell (3). 
Alternatively, hypermutated cDNA enters the nucleus (4) and integrates into the host genome but results in the production of 
defective or aberrant viral proteins (5). This can lead to an impairment of virus assembly or result in the assembly of non-infec-
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cells and despite the fact that HTLV-1 does not appear to
encode a gene with Vif-like function. Similar resistance to
APO3G was observed for MuLV, which replicates in
APO3G-expressing murine cells without accumulation of
hypermutations despite the fact that murine APO3G is
packaged into MuLV virions [9]. These results suggest that
packaging of APO3G into viral particles per se may not be
sufficient to inhibit viral infectivity. Rather, it seems that
APO3G has to be specifically packaged into the viral core
in association with the viral RNA to exert its inhibitory
activity [10]. In the new study, Sasada et al report that
APO3G is efficiently packaged into HTLV-1 particles. This
is true for endogenous and exogenously expressed APO3G
alike. Interestingly, and consistent with the MuLV model,
packaging of APO3G into HTLV-1 did not result in a sig-
nificant accumulation of APO3G-induced hypermuta-
tions. In contrast to MuLV, however, Sasada et al note a
profound effect of APO3G on the infectivity of HTLV-1
particles, which was reduced to almost background levels.
Similar findings were recently reported by Navarro et al
although the effects of APO3G on HTLV-1 infectivity in
that study were found to be modest when compared to
HIV-1 [11]. Surprisingly, Sasada et al found that variants
carrying mutations in either the first or the second zinc
finger domain of APO3G were capable of inhibiting
HTLV-1 with similar efficiency than the wild type protein.
This is in contrast to their previous finding that APO3G
enzymatic activity was essential for anti-HIV-1 activity
[12]. On the other hand, Newman et al recently demon-
strated anti-HIV activity for deaminase-defective APO3G
variants similar to the ones used in the current study [13].
Thus, while details have yet to be sorted out, there is an
emerging picture of a multifunctional host factor that can
exert antiviral activity by way of its inherent deaminase
activity or through a deaminase-independent mechanism.
One possible deaminase-independent mode of action
would be interference with virus-maturation in analogy to
the reported inhibition of Gag maturation by high levels
of HIV-1 Vif [14]. Such a model seems particularly attrac-
tive as APO3G was found to interact with viral Gag precur-
sor proteins [15].
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